CGPHF (Grand Pharmaceutical Group) OCF Margin %: 25.48% (As of Dec. 2025) — 25% Above Median


What is Grand Pharmaceutical Group OCF Margin %?

Grand Pharmaceutical Group CGPHF 87 OCF Margin % is 25.48% as of Dec. 2025, which is 25% above its 10-year median of 20.38. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 61.73% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Grand Pharmaceutical Group's Cash Flow from Operations for the six months ended in Dec. 2025 was $202.23 Mil. Grand Pharmaceutical Group's Revenue for the six months ended in Dec. 2025 was $793.74 Mil. Therefore, Grand Pharmaceutical Group's OCF Margin % for the quarter that ended in Dec. 2025 was 25.48%.

As of today, Grand Pharmaceutical Group's current OCF Yield % is 9.81%.

The historical rank and industry rank for Grand Pharmaceutical Group's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Grand Pharmaceutical Group was 23.64%. The lowest was 13.43%. And the median was 20.38%.

CGPHF's OCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.94
* Ranked among companies with meaningful OCF Margin % only.

Grand Pharmaceutical Group OCF Margin % Related Terms

Grand Pharmaceutical Group OCF Margin % Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group OCF Margin % Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.33 19.27 23.03 16.30 13.43

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.91 3.75 29.85 1.25 25.48

Grand Pharmaceutical Group OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Grand Pharmaceutical Group's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=211.999/1578.664
=13.43 %

Grand Pharmaceutical Group's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=202.225/793.742
=25.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 25.48% mean?
Grand Pharmaceutical Group (CGPHF) has a OCF Margin % of 25.48% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Grand Pharmaceutical Group and its competitors. This is 25% above median its historical median of 20.38. Over the past decade, Grand Pharmaceutical Group's OCF Margin % has ranged from 13.43 to 23.64. According to the industry distribution chart, Grand Pharmaceutical Group ranks #367 out of 959 companies in the Drug Manufacturers industry, placing it in the top 38.3%.
Is Grand Pharmaceutical Group's OCF Margin % too high?
Grand Pharmaceutical Group's current OCF Margin % of 25.48% is 25% above median its 10-year median of 20.38. Over the past 10 years, this metric has ranged from a low of 13.43 to a high of 23.64. The Drug Manufacturers industry median OCF Margin % is 9.94. Grand Pharmaceutical Group's value of 25.48% is 156.3% above this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #367 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #367 out of 959 companies for OCF Margin %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median OCF Margin % is 9.94. Grand Pharmaceutical Group's value of 25.48% is 156.3% above this benchmark. Historically, Grand Pharmaceutical Group's own OCF Margin % has ranged from 13.43 to 23.64 over the past decade. While the company's 10-year median is 20.38 vs. the industry median of 9.94, Grand Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current OCF Margin % of 25.48% is 156.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current OCF Margin % is 25.48%, which is 25% above median its own 10-year median of 20.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current OCF Margin % of 25.48%. The current OCF Margin % is 25.48%, which is 25% above median its 10-year median of 20.38 and 156.3% above the Drug Manufacturers industry median of 9.94. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current OCF Margin % is 25.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.